

KOREA HYPERTENSION FACT SHEET 2018

The Korean Society of Hypertension



KOREA HYPERTENSION FACT SHEET 2018

Publisher Myeong-Chan Cho
Editor-in-chief Hyeon Chang Kim
Editor The Korean Society of Hypertension -
 Hypertension Epidemiology Research Working Group

Executive Members of The Korean Society of Hypertension

| | | |
|--|-----------------|----------------------------------|
| Chairman | Jin-Won Jeong | Wonkwang University |
| Chairman-Elect | Gilja Shin | Ewha Womans University |
| Vice-Chairman | Dong Soo Kim | Inje University |
| | Gheun-Ho Kim | Hanyang University |
| President | Myeong-Chan Cho | Chungbuk National University |
| Secretary General | Seok-Min Kang | Yonsei University |
| Director of Planning | Wook Bum Pyun | Ewha Womans University |
| Director of Scientific Affairs | Hae-Young Lee | Seoul National University |
| Director of Publication | Wook-Jin Chung | Gachon University |
| Director of Treasurer | Sang-Hyun Ihm | The Catholic University of Korea |
| Director of Research | Kwang Il Kim | Seoul National University |
| Director of Education | Eun Joo Cho | The Catholic University of Korea |
| Director of Public Relation | Il-Suk Sohn | The Kyunghee University |
| Director of International Affairs | Sungha Park | Yonsei University |
| Director of Health Insurance | Jinho Shin | Hanyang University |
| Director of Public Policy | Ki Chul Sung | Sungkyunkwan University |
| Director of Informatics | Sung Kee Ryu | Eulji University |
| Director of Ethics | Jidong Sung | Sungkyunkwan University |

| | | |
|------------------|-----------------|---------------------------------|
| Directors | Dae Jung Kim | Ajou University |
| | Hyeon Chang Kim | Yonsei University |
| | Dong-Ryeol Ryu | Ewha Womans University |
| | Dong Heon Yang | Kyungpook National University |
| | Byung Su Yoo | Yonsei University Wonju |
| | Moo-Yong Rhee | Dongguk University |
| | Seung Hoon Lee | Seoul National University |
| | Eun Mi Lee | Wonkwang University |
| | Joong Hwa Chung | Chosun University |
| | Jin Ok Jeong | Chungnam National University |
| | Jin Han | Inje University |
| | Young Mi Hong | Ewha Womans University |
| | Jin Yong Hwang | Gyeong-sang National University |
| Auditors | Chang Gyu Park | Korea University |
| | Se-Joong Rim | Yonsei University |

Executive Members of The Hypertension Epidemiology Research Working Group

| | | |
|------------------------------------|-----------------|----------------------------------|
| Chairman | Hyeon Chang Kim | Yonsei University |
| Vice-Chairman | Song Vogue Ahn | Ewha Womans University |
| Executive Committee Members | Sun Ha Jee | Yonsei University |
| | Sungha Park | Yonsei University |
| | Hae-Young Lee | Seoul National University |
| | Min Ho Shin | Seoul National University |
| | Sang-Hyun Ihm | The Catholic University of Korea |

| | | |
|--------------------|---------------|------------------------------|
| Advisors | Jong Ku Park | Yonsei University |
| | Il Suh | Yonsei University |
| | Tae-Yong Lee | Chungnam National University |
| Coordinator | Seung Won Lee | Yonsei University |

Greetings

Hypertension is the most common chronic disorder in Korea. Globally, it stands as the top risk factor for cardiovascular diseases and the number one cause of death. However, we can effectively decrease the burden of hypertension through prevention and management of the condition. Since its establishment in 1994, the Korean Society of Hypertension is confident in that it has made significant attributions in raising our country's hypertension awareness, treatment, and control rates through consistent academic achievements and successful healthcare programs. We have envisioned to improve people's health by better blood pressure control and to become the field's global leader by providing scientific evidence. With emphasis on responsibility, participation, leadership, and professionalism, we collaborate with governmental and non-governmental organizations to establish practical hypertension management goals and strive to achieve them. We have concluded that it is crucial to provide a well-rounded and nationally-representative data on hypertension. This hypertension fact sheet will provide an objective insight into the magnitude and management status of hypertension in Korea, and will be the basis for academic research and policy making on hypertension. We deeply acknowledge the "Korea Centers for Disease Control & Prevention (KCDC)" and the "National Health Insurance Service (NHIS)" for providing valuable dataset, and the "Hypertension Epidemiology Research Working Group" for analyzing and interpreting such vast dataset.

The Korean Society of Hypertension

Chairman
Jin-Won Jeong

President
Myeong-Chan Cho



Data source and analysis methods - Korea National Health and Nutrition Examination Survey (KNHANES)

| | | |
|---|---|--|
| Subjects | | 30 years of age and older / From 1998 to 2016 |
| Classification of blood pressure | Hypertension | ① Systolic blood pressure (SBP) greater than 140mmHg, or ② Diastolic blood pressure (DBP) greater than 90mmHg, or ③ Currently taking antihypertensive medication |
| | Prehypertension | ① Not qualified for hypertension and ② SBP between 120-139mmHg, or ③ DBP between 80-89mmHg |
| | Normal blood pressure | None of the above |
| Definition of indicators | Awareness rate | Proportion of people clinically diagnosed with hypertension over people with hypertension |
| | Treatment rate | Proportion of people taking antihypertensive medications for 20 days or more per month over people with hypertension |
| | Control rate (among people with hypertension) | Proportion of people with SBP <140mmHg and DBP <90mmHg over people with hypertension |
| | Control rate (among people treated for hypertension) | Proportion of people with SBP <140mmHg and DBP <90mmHg over people treated for hypertension |

Data source and analysis methods - National Health Insurance Big Data (NHI-BD)

| | | |
|---------------------------------|--|--|
| Subjects | | All ages / From 2002 to 2016 |
| Definition of indicators | Healthcare services utilization | Clinical visit with the diagnosis of hypertension at least once per year |
| | Treatment | Prescribed antihypertensive medication at least once per year |
| | Persistent treatment | Prescribed antihypertensive medication 290 days or more per year (80% of one calendar year) |
| Hypertension treatment | Classification of antihypertensive drugs | Diuretics (DU), beta-blocker (BB), calcium channel blocker (CCB), angiotensin receptor blocker (ARB), ACE inhibitor (ACE), others (aldosterone antagonists, alpha blockers, vasodilators, etc) |
| | Primary prescription | If alterations are made to prescription, primary prescription is defined as and classified by antihypertensive medication that has been used for the longest time in that particular year. |


Contents

| | |
|--|---|
| | 06 Summary |
| | 07 Summary of population statistics |
| | 08 Summary of treatment statistics |
| 1 Changes in population mean blood pressure and magnitude of hypertension | 11 Changes in population mean blood pressure |
| | 12 Changes in prevalence |
| | 13 Changes in prevalence by sex and age |
| | 14 Changes in the estimated number of people with hypertension |
| 2 Changes in indicators of hypertension management | 16 Prevalence and management indicators by sex |
| | 17 Changes in management indicators |
| | 18 Changes in awareness rate by sex |
| | 19 Changes in treatment rate by sex |
| | 20 Changes in control rate by sex |
| | 22 Changes in awareness rate by sex and age |
| | 23 Changes in treatment rate by sex and age |
| | 24 Changes in control rate by sex and age |
| 3 Healthcare services utilization for hypertension | 27 Changes in healthcare services utilization |
| | 28 Age distribution of people treated for hypertension |
| | 30 Co-treatment for hypertension, dyslipidemia, or diabetes |
| | 32 Changes in antihypertensive drug prescription |
| | 36 Changes in monotherapy composition |
| | 40 Changes in dual therapy composition |


Summary

- Approximately 11 million Korean adults have hypertension.
- In adults aged 30 years or older, the prevalence of hypertension is 29%. Of those, 65% are aware of their diagnosis, 61% are receiving treatment, and 44% have their blood pressures under control.
- Awareness, treatment and control rates of hypertension have rapidly improved until 2007; but since then, these rates have been stagnant.
- People with hypertension aged 30-49 years have awareness, treatment, and control rates below 50%.
- Annually, 8.9 million people make clinical visit at least once to receive treatment for hypertension. Of those, 5.7 million receive persistent treatment.
- Among those treated for hypertension, the proportion of individuals aged 65 years or older has increased rapidly from 34% in 2002 to 46% in 2016.
- Among those treated for hypertension, 57% are also treated for diabetes or dyslipidemia.
- Among those treated for hypertension, 60% use a combination of two or more antihypertensive drugs.
- The most frequently used monotherapy drugs are angiotensin receptor blockers (ARBs, 43%) and calcium channel blockers (CCBs, 43%). The most frequently used dual therapy is a combination of CCBs and ARBs (54%).


Summary of population statistics




Summary of treatment statistics




Medication prescription
(total 8,219,104)



Monotherapy composition
(total 3,311,114)



Dual therapy composition
(total 3,456,866)



**Co-treatment for hypertension, diabetes,
or dyslipidemia**
(total 8,219,104)

1 Changes in population mean blood pressure and hypertension magnitude


Changes in population mean blood pressure

(Age 30+, age-standardized)



118/77

mmHg




Changes in prevalence



(Age 30+, age-standardized)







29%



Changes in prevalence by sex and age

Age <70  > 

Age 70+  < 




Changes in the estimated number of people with hypertension

Now exceeding 11 million

(Unit: per 1,000 people)

■ Age 65+
 ■ Age 50-64
 ■ Age 30-49
 ■ Age 19-29




2 Changes in indicators of hypertension management

Prevalence and management indicators by sex

(Age 30+)

56%

Uncontrolled



Changes in management indicators

(Age 30+, age-standardized)


Rapid improvement between '98-'07
Stagnant in the past 10 years



Changes in awareness rate by sex

(Age 30+, age-standardized)


 65%  67%



Changes in treatment rate by sex

(Age 30+, age-standardized)


 60%  64%



Changes in control rate among people with hypertension by sex

(Age 30+, age-standardized)


 43%  47%





Changes in control rate among people treated for hypertension by sex

(Age 30+, age-standardized)



 71%  71%





Changes in awareness rate by sex and age





Changes in treatment rate by sex and age



Changes in control rate among people with hypertension by sex and age



Changes in control rate among people treated for hypertension by sex and age




3 Healthcare services utilization for hypertension

Changes in healthcare services utilization and treatment


Healthcare service users 8,921,829 people

Receiving treatment 8,219,104 people

Persistent treatment 5,734,238 people




Age distribution of people treated for hypertension




34% → 46%

Elderly (age 65+) people
with hypertension




Co-treatment for hypertension, dyslipidemia, or diabetes



25% → 57%

People who are also treated for diabetes or dyslipidemia



Hypertension+Dyslipidemia+Diabetes
92,771(3.7%) → 1,407,011(17.1%)


Hypertension+Dyslipidemia
229,540(9.1%) → 2,621,509(31.9%)

Hypertension+Diabetes
318,813(12.6%) → 638,706(7.8%)


Hypertension only
1,887,729(74.6%) → 3,551,878(43.2%)

Changes in antihypertensive drug prescription

(among all people with treatment)




60% are receiving combination therapy




Changes in antihypertensive drug prescription

(among people with persistent treatment)





63% are receiving combination therapy



Changes in monotherapy composition


(among all people with treatment)






Changes in monotherapy composition


(among people with persistent treatment)






Changes in dual therapy composition


(among all people with treatment)






Changes in dual therapy composition

(among people with persistent treatment)







Please cite this fact sheet as: The Korean Society Hypertension (KSH) – Hypertension Epidemiology Research Working Group.
Korea Hypertension Fact Sheet 2018. Clinical Hypertension 2018;24:** https://doi.org/10.1186/*****